Skip to main content
. 2021 Nov 24;13(23):5900. doi: 10.3390/cancers13235900

Figure 2.

Figure 2

NPM1 and CYCLON co-expression is associated with progression-free survival in DLBCL patients. (A) Mosaic plot showing the distribution of NPM1(−/+) cases according to CYCLON (−/+) status. (B) Kaplan–Meier analysis of progression-free survival (PFS) associated with CYCLON single expressors (CYCLON(+) NPM1(−)) or CYCLON/NPM1 double expressors (CYCLON (+) NPM1(+)). (C) Mosaic plot showing the distribution of NPM1(−/+) cases according to CYCLON IHC staining patterns (pan: pan-nuclear, nuc: nucleolar, ext: extra-nucleolar). (D) Kaplan–Meier analysis of PFS associated with CYCLON non-extra-nucleolar (CYCLON (ext−)), CYCLON extra-nucleolar/NPM1 negative (CYCLON (ext+) NPM1(−)) or CYCLON extra-nucleolar/NPM1 double expressors (CYCLON (ext+) NPM1(+)). p values are derived from a log rank test. (E) Survival Cox model regression analyses of CYCLON (ext+) NPM1(+) cases (n = 13) and CYCLON (ext+) NPM1(−) cases (n = 5) for PFS and specific overall survival (SOS). CYCLON non-extra-nucleolar staining (CYCLON (ext−)) (n = 79) is the reference category in both models. HR: hazard ratio, CI: confidence interval, * 95% CI based on bootstrap resampling (1000 replicates). Schoenfeld residual test: PFS model: global p = 0.91; SOS model: global p = 0.98.